Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals Inc (NQ: AVIR )

3.370 +0.120 (+3.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Atea Pharmaceuticals: Q4 Earnings Insights
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
NASDAQ:AVIR Investor Notice: Investigation over Possible Securities Laws Violations by Atea Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 02/02/2022 -- Atea Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Expert Ratings For Atea Pharmaceuticals
Atea Pharmaceuticals (NASDAQ:AVIR) has observed the following analyst ratin... 
Via Benzinga
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers NeuroOne Medical Tech (NASDAQ:NMTC... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Atea Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Atea Pharmaceuticals (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2021
Upgrades Macquarie upgraded the previous rating for ZTO Express (Cayman) Inc (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers EyePoint Pharmaceuticals (NASDAQ:EYP... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
42 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The... 
Via Benzinga
Why Atea Pharmaceuticals Stock Is Sinking Today
Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy. 
Via The Motley Fool
Exposures COVID-19
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill
Roche and Atea's partnership will end in February. 
Via Investor's Business Daily
Exposures Product Safety
Atea Pharmaceuticals Inc (AVIR) Q3 2021 Earnings Call Transcript
AVIR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Is There Any Hope for Atea Pharmaceuticals Stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors. 
Via The Motley Fool
Exposures COVID-19
3 Beaten-Down Biotech Stocks -- Can They Recover?
Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. 
Via The Motley Fool
How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market
Merck and Pfizer could benefit from Atea's setback. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.